Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
Conditions
Interventions
CVL-231
Locations
10
United States
Pillar Clinical Research LLC
Bentonville, Arkansas, United States
Woodland International Research Group LLC - ERG - PPDS
Little Rock, Arkansas, United States
Collaborative NeuroScience Research, LLC - Torrance - Apex - PPDS
Long Beach, California, United States
Innovative Clinical Research, Inc - ClinEdge - PPDS
Miami, Florida, United States
Uptown Research Institute LLC
Chicago, Illinois, United States
Pillar Clinical Research LLC
Lincolnwood, Illinois, United States
Start Date
January 24, 2022
Primary Completion Date
October 19, 2022
Completion Date
November 14, 2022
Last Updated
December 14, 2022
NCT06894212
NCT06003036
NCT04226898
NCT03496792
NCT05240976
NCT07482930
Lead Sponsor
Cerevel Therapeutics, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions